SG11201808183PA - Methods of heat inactivation of adenovirus - Google Patents

Methods of heat inactivation of adenovirus

Info

Publication number
SG11201808183PA
SG11201808183PA SG11201808183PA SG11201808183PA SG11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA SG 11201808183P A SG11201808183P A SG 11201808183PA
Authority
SG
Singapore
Prior art keywords
international
mgc12
methods
particles
aav
Prior art date
Application number
SG11201808183PA
Inventor
Christopher Morrison
James Maratt
Original Assignee
Dimension Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimension Therapeutics Inc filed Critical Dimension Therapeutics Inc
Publication of SG11201808183PA publication Critical patent/SG11201808183PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011111010111011111011111101111011111 International Bureau .. .... ..Yejd ..... .....1 (10) International Publication Number (43) International Publication Date WO 2017/172772 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise C12N 15/861 (2006.01) C12N 7/04 (2006.01) kind of national protection available): C12N 15/864 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, PCT/US2017/024545 HN, HR, HU, ID, IL, IN, IR, IS, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, 28 March 2017 (28.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, ZA, ZM, ZW. (30) Priority Data: 62/314,116 28 March 2016 (28.03.2016) US (84) Designated States (unless otherwise kind of regional protection available): (71) Applicant: DIMENSION THERAPEUTICS [US/US]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 TZ, UG, ZM, ZW), Eurasian (AM, (US). TJ, TM), European (AL, AT, BE, (72) Inventors: MORRISON, Christopher, J.; 118 Lowell DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Street, Arlington, MA 02474 (US). MARATT, James, D.; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 44 Lewis Road, Belmont, MA 02478 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, (74) Agents: DELFINO, Wyatt al.; Goodwin Procter LLP, et indicated, for every AE, AG, AL, AM, GD, GE, GH, GM, GT, JP, KE, KG, KH, KN, LR, LS, LU, LY, MA, PL, PT, QA, RO, RS, UG, US, UZ, VC, VN, indicated, for every ARIPO (BW, GH, AZ, BY, KG, KZ, RU, BG, CH, CY, CZ, DE, TG). 21(3)) Published: 100 Northern Avenue, Boston, MA 02210 (US). _ — — with international search report (Art. = = = = = Title: METHODS OF HEAT INACTIVATION OF ADENOVIRUS = (54) or particles, and a buffer. biological activity of The methods in - greater of divalent or = — FIG. 6 = 110% - - - - - - - - - - - - - - - -------- - ------- --- 7 - - - - - - - - - - - - = = - - - . ..__ - -,.... , .... = = .. .7 . ---- ,..„ ¨ Z - 1 -- ¨ _ - Background Buffer , 3.InsA Mg 12 Il ¨ ........ 10:riA MgC12 ¨ 5r4*1 MgC12 1 k MgC12 ei --4-- 100r0A1 Men - + -100nM MgC12 (Re aci) N O IN 50 19B 150 21q Exposure time (minutes) at 47•C 11 IN 1-1 (57) : The present disclosure generally relates to methods of protecting the genomic integrity and/or N AAV viral particles in a sample containing both AAV particles and helper virus particles during heat inactivation. dude heating, to a temperature greater than or equal to 45°C, a sample containing helper virus particles, AAV C The buffer includes a concentration of 10 mM or greater kosmotropic salts and/or a concentration of 10 mM trivalent cations.
SG11201808183PA 2016-03-28 2017-03-28 Methods of heat inactivation of adenovirus SG11201808183PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314116P 2016-03-28 2016-03-28
PCT/US2017/024545 WO2017172772A1 (en) 2016-03-28 2017-03-28 Methods of heat inactivation of adenovirus

Publications (1)

Publication Number Publication Date
SG11201808183PA true SG11201808183PA (en) 2018-10-30

Family

ID=59966403

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808183PA SG11201808183PA (en) 2016-03-28 2017-03-28 Methods of heat inactivation of adenovirus

Country Status (18)

Country Link
US (2) US11013774B2 (en)
EP (2) EP4159867A1 (en)
JP (3) JP7356224B2 (en)
KR (1) KR102389674B1 (en)
CN (1) CN109196106A (en)
AU (1) AU2017241777B2 (en)
BR (1) BR112018069703A2 (en)
CA (1) CA3018380A1 (en)
DK (1) DK3436593T3 (en)
ES (1) ES2938833T3 (en)
FI (1) FI3436593T3 (en)
HU (1) HUE061100T2 (en)
IL (1) IL261914B2 (en)
LT (1) LT3436593T (en)
PL (1) PL3436593T3 (en)
PT (1) PT3436593T (en)
SG (1) SG11201808183PA (en)
WO (1) WO2017172772A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020109343A (en) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. AADC POLINUCLEOTIDES FOR TREATMENT OF PARKINSON'S DISEASE
MX2017006216A (en) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als).
DK3218386T3 (en) 2014-11-14 2021-06-07 Voyager Therapeutics Inc MODULATORY POLYNUCLEOTID
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
IL302748A (en) 2016-05-18 2023-07-01 Voyager Therapeutics Inc Modulatory polynucleotides
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN113454226A (en) 2018-12-18 2021-09-28 阿尔特拉吉尼克斯制药公司 Methods and compositions for treating glycogen storage disease
EP3953458A1 (en) 2019-04-12 2022-02-16 Ultragenyx Pharmaceutical Inc. Engineered producer cell lines and methods of making and using the same
TW202342740A (en) 2022-03-07 2023-11-01 美商奧崔基尼克斯製藥公司 Modified batch aav production systems and methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
JP4216350B2 (en) 1994-09-19 2009-01-28 大日本住友製薬株式会社 Recombinant DNA viral vector for animal cell infection
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
JPH10511264A (en) 1994-12-06 1998-11-04 ターゲティッド ジェネティックス コーポレイション Packaging cell lines for the production of high titer recombinant AAV vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5688676A (en) * 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
ES2099678B1 (en) * 1995-11-03 1998-02-16 Grifols Grupo Sa PROCEDURE FOR THE INACTIVATION OF VIRUSES IN PROTEINS.
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6541258B2 (en) 1996-12-18 2003-04-01 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
IT1297074B1 (en) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio HORMONE-DEPENDENT FORMS OF THE REP PROTEIN OF THE ADENUS ASSOCIATED VIRUS (AAV-2), DNA SEQUENCES CODING FOR THEM, VECTORS THAT
WO2000009675A1 (en) * 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
CA2348838A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
DE19905501B4 (en) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
WO2000061726A1 (en) * 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition for the preservation of infectious recombinant adenoviruses
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
DE10061533B4 (en) 2000-12-11 2006-05-04 Amphenol-Tuchel Electronics Gmbh Self-supporting contact spring, in particular for a smart card connector
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
JP2008501339A (en) * 2004-06-01 2008-01-24 ジェンザイム・コーポレイション Composition and method for preventing AAV vector aggregation
US7195394B2 (en) 2004-07-19 2007-03-27 Vijay Singh Method for resonant wave mixing in closed containers
US8980247B2 (en) 2004-10-21 2015-03-17 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells
SI1945779T1 (en) 2005-10-20 2013-07-31 Uniqure Ip B.V. Improved aav vectors produced in insect cells
US9254318B2 (en) * 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
CN103849629B (en) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 Carrier with the modified AAV REP78 translation initiation codons for producing AAV in insect cell
GB0706638D0 (en) 2007-04-04 2007-05-16 Mbda Uk Ltd A high-dielectric material
US8580755B2 (en) 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
CA2742151A1 (en) 2008-11-07 2010-05-14 Intelligentnano Inc. Transfection with magnetic nanoparticles and ultrasound
BRPI1015176B1 (en) * 2009-06-16 2019-10-29 Genzyme Corp method for isolating a population of recombinant adeno-associated virus (raav) particles from process impurities in a feed stream
WO2013096955A1 (en) 2011-12-23 2013-06-27 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
SG10201913130PA (en) 2013-01-08 2020-03-30 Genzyme Corp Use of inos inhibitors to increase viral yield in culture

Also Published As

Publication number Publication date
IL261914B1 (en) 2023-03-01
AU2017241777B2 (en) 2022-02-03
KR102389674B1 (en) 2022-04-21
EP3436593A4 (en) 2019-10-16
HUE061100T2 (en) 2023-05-28
PT3436593T (en) 2023-01-31
BR112018069703A2 (en) 2019-02-05
LT3436593T (en) 2023-03-10
JP2021072838A (en) 2021-05-13
US11944658B2 (en) 2024-04-02
CA3018380A1 (en) 2017-10-05
AU2017241777A1 (en) 2018-10-11
WO2017172772A1 (en) 2017-10-05
EP3436593A1 (en) 2019-02-06
ES2938833T3 (en) 2023-04-17
DK3436593T3 (en) 2023-02-20
EP4159867A1 (en) 2023-04-05
US20190083554A1 (en) 2019-03-21
JP7356224B2 (en) 2023-10-04
IL261914A (en) 2018-10-31
US11013774B2 (en) 2021-05-25
CN109196106A (en) 2019-01-11
JP2022166304A (en) 2022-11-01
US20220072073A1 (en) 2022-03-10
EP3436593B1 (en) 2022-11-23
FI3436593T3 (en) 2023-03-16
JP2019509747A (en) 2019-04-11
PL3436593T3 (en) 2023-03-27
KR20180130531A (en) 2018-12-07
IL261914B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
SG11201808183PA (en) Methods of heat inactivation of adenovirus
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201908391XA (en) Methods for modulating an immune response
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201811435PA (en) Automated cell processing systems and methods
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201906765UA (en) Personalised immunogenic peptide identification platform
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201805993UA (en) Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201807022XA (en) Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
SG11201906735RA (en) Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201901620SA (en) Methods of identifying microsatellite instability
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201803642WA (en) Bacteria-based protein delivery
SG11201900543SA (en) Gene therapy for the treatment of aldehyde dehydrogenase deficiency
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide